Accuray (ARAY) Set to Release Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is anticipated to issue its Q1 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $95.80 million for the quarter. Individuals may visit the company’s upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last announced its earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $100.92 million during the quarter, compared to analyst estimates of $105.30 million. Accuray had a negative net margin of 12.24% and a negative return on equity of 97.85%.

Accuray Price Performance

ARAY stock opened at $0.14 on Monday. The stock has a 50-day moving average price of $0.22 and a two-hundred day moving average price of $0.37. The stock has a market cap of $16.74 million, a PE ratio of -0.35 and a beta of 1.38. The company has a current ratio of 1.50, a quick ratio of 0.74 and a debt-to-equity ratio of 3.51. Accuray has a 1 year low of $0.12 and a 1 year high of $1.46.

Analysts Set New Price Targets

ARAY has been the topic of a number of research reports. BTIG Research dropped coverage on Accuray in a report on Wednesday, July 8th. They issued a “neutral” rating on the stock. Weiss Ratings cut Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Accuray presently has an average rating of “Reduce”.

Accuray Company Profile

Accuray Incorporated develops, manufactures and supports radiation oncology systems used to treat cancer. The company focuses on precision radiotherapy technologies designed to deliver targeted radiation while helping clinicians manage treatment complexity and limit exposure to surrounding healthy tissue.

Its principal product platforms include the CyberKnife System, a robotic, image-guided radiation therapy system used for radiosurgery and stereotactic body radiation therapy, and the Radixact System, an image-guided tomotherapy platform designed to deliver highly conformal radiation treatments.